OrthoLogic Corp.

Industry:	Medical Devices & Equipment
Revenues:	$4 Million
Employees:	38

Description

OrthoLogic Corp. (OrthoLogic) is a development stage biotechnology company focused on the development and commercialization of the synthetic peptides Chrysalin (TP508) and AZX100. The Company also focuses to evaluate other biopharmaceutical compounds that can complement its research activity internally and broaden its potential pipeline for other products.
(Source: 10-K)

View More Statistics

Site Statistics

Monthly Unique Visitors:	124
Site Rank:	4,000,496
Trust Rating:	Neutral
Stats by

News Archive

OrthoLogic Expanding Peptide Platform Via Chrysalis Buyout. BIOWORLD Today; 11/3/2009 ...Growing its Chrysalin product platform, OrthoLogic Corp. signed a definitive agreement...agreement, expected in the third quarter, OrthoLogic gains exclusive rights to technology...for a variety of indications. All of OrthoLogic's current products are based on the... ...more

OrthoLogic's Stock Dips As Phase IIb Misses Endpoint. BIOWORLD Today; 11/3/2009 Washington Editor OrthoLogic Corp. halted a Phase IIb study of...The future," said Dana Shinbaum, OrthoLogic's vice president of business development...Beyond that indication, Shinbaum said OrthoLogic remains optimistic about the product... ...more

Publication No. WO/2009/142679 Published on Nov. 26, Assigned to ORTHOLOGIC for Acute Myocardial Infarction Treatment Method (American Inventors) US Fed News Service, Including US State News; 11/27/2009 ...United States of America, have developed methods for treating acute myocardial infarction. The patent has been assigned to ORTHOLOGIC CORP., Tempe, Ariz. According to an abstract posted by the World Intellectual Property Organization: "The present invention... ...more